QIAGEN Releases New Pandemic Influenza A/H1N1 Detection Kit
“With QIAGEN’s new test and our existing solutions to support Tamiflu/Oseltamivir resistance testing, we offer healthcare professionals powerful tools not only to quickly and reliably detect the origin of flu-like symptoms in patients, but also to profile the pathogen and thus to rapidly take the necessary actions to control an outbreak,” said Peer Schatz, CEO of QIAGEN. “In the light of the upcoming flu season and the likely emergence and dissemination of other Influenza A and B strains, these capabilities are vital to effectively fight the further dissemination and the effects of the H1N1 pandemic.”
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.